title: Levonantradol, a potent cannabinoid-related analgesic, antagonizes haloperidol-induced activation of striatal dopamine synthesis.
abstract: Levonantradol antagonized the compensatory acceleration of striatal dopamine synthesis induced by haloperidol. This effect was stereospecific, since the pharmacologically less active enantiomer, dextronantradol was approximately 30 times less effective. delta 9-Tetrahydrocannabinol at a dose 320 times higher than levonantradol also attenuated the haloperidol effect, but cannabidiol was inactive at a dose 750 times higher. GABA-like actions of levonantradol may be responsible for this responsible for this antagonism of haloperidol, but anticholinergic effects may also contribute.
mesh_terms: D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000096:biosynthesis*; D013759:Dronabinol / Q000494:pharmacology; D006220:Haloperidol / Q000037:antagonists & inhibitors*; D008297:Male; D010617:Phenanthridines / Q000494:pharmacology*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D013237:Stereoisomerism; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
chemical_list: D000700:Analgesics; D010617:Phenanthridines; D011954:Receptors, Dopamine; D005680:gamma-Aminobutyric Acid; D013759:Dronabinol; C025490:nantradol; D006220:Haloperidol; D004298:Dopamine